readthroughSign in
Nov 6, 2026Weekly roundup3 fact check notes

Sanofi's Phase 3 vYF yellow fever vaccine trial in children active, not recruiting

A registry update shows Sanofi's pediatric yellow fever vaccine study VYF04 comparing vYF to two licensed vaccines, with results expected in 2026.

Sanofi's registry activity this week centers on a single pediatric vaccine trial.

  • The study plans to enroll a total of 2440 participants.1 The trial's status is listed as active, not recruiting, with primary completion estimated for 2026-11-28.

Fact check notes

  • ImpreciseResults expected in 2026Only the primary completion date falls in 2026; the overall study completion (final results) is estimated for 2030, so framing all results as expected in 2026 is imprecise.
  • Checker's noteThe summary's phrase 'results expected in 2026' conflates the estimated primary completion date (2026-11-28) with the estimated study completion date (2030-03-04), overstating when final results will be available.
  • Sentence removedThe Phase III study "VYF04" (NCT07103148) is testing Sanofi's investigational vYF vaccine against two licensed yellow fever vaccines, Stamaril and YF-VAX, in children aged 9 months to 5 years.a figure with no citation

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.